Associate Director Moscow - Russia

 

Associate Director of Angelico Ventures. Prior to joining Angelico, Elena has worked as CEO, financial analyst and project manager of several multinational and Russian companies. Graduated from Moscow Academy of Law and Finance with specialization in finance (magna cum laude).

 

 

 

 

 

 

 

 

 

 

 

Partner Moscow - Russia

 

Yury Oreshin joined Teknoinvest Angelico Ventures in 2010. Prior to joining Teknoinvest Angelico Ventures, Yury was the Founder and Managing Partner of Angelico Ventures. Prior to starting Angelico Ventures Mr. Oreshin advised venture capital and investment companies on business development and strategy. He holds a Bachelor of Science in Business Administration degree from the University of South Carolina, Moore School of Business.

 

 

 

 

 

 

 

 

 

Partner Shanghai – China

 

Senior positions at top tier venture capital firms ARCH Venture Partners (China) – Venture Partner Intellectual Ventures (China) – Executive Director and General Manager GE Capital Equity Group (USA) – Managed portfolio of over US$100M MBA Wharton School of Business

 

 

 

 

 

 

 

 

 

 

 

Partner Tonbridge – England

 

Tristan Brittain-Dissont joined Teknoinvest Angelico Ventures in 2010. Prior to Teknoinvest Angelico Ventures Tristan was a Partner of Angelico Ventures life sciences boutique investment bank. Tristan has over 15 years experience in the pharmaceutical and life sciences industry. For the first six years of his career, he held a variety sales and marketing roles at Merck, Sharp and Dohme and Rhone-Poulenc Rorer, launching a number of new products during this period, particularly in the field of neurology. Subsequent to this, he was part of the set-up team for Biogen Inc's first commercial operations in the UK, and was instrumental in the launch of Avonex for the treatment of multiple sclerosis. Having spent time in both blue chip and biotechnology pharmaceutical companies, Tristan then moved into the field of outsourced clinical research solutions. He developed international business development teams for Covance, one of the world's largest contract research companies. As a result of this, he was headhunted by GSK and spent four years commercializing and building Intercern. Initially a UK organization, Intercern grew to be Europe's largest patient recruitment company, backed by 3i, Europe's leading venture capital firm. In this capacity, Tristan sat on the main Board of the company as Commercial Director. From 2003 to 2008 Mr. Brittain-Dissont managed a USD$30M investment fund SpringHill Bioventures venture capital fund, specializing in drug development and medtech in the US, Europe, India and South East Asia.During this time, he held the post of CEO at Alpha Biologics (contract biologics manufacturing) and PsiMei Pharmaceutical Plc (oncology drug development).

Partner Moscow - Russia

 

Investment manager at Rusnano Served as CFO at the pharmaceutical division of AFK Sistema Investment banking experience at ING and Renaissance Capital Master in Public Administration at Harvard University

 

 

 

 

 

 

 

 

 

 

 

Partner Moscow – Russia

 

Board member of CardioProtect. Stan holds a Masters degree in Molecular Genetics from the Kyiv National Taras Shevchenko University. Did his practice work in Molecular Medicine at Hannover Medical School in Germany where he has been conducting his research in the area of molecular biology and genetics.

 

 

 

 

 

 

 

 

 

 

Partner Bangalore – India

 

Currently Director of a Tissue Engineering and Regenerative Medicine Center Founder/ CEO of DiponEd BioIntelligence, Served as Senior Principal Scientist at Stempeutics Res. Pvt Ltd. Served as Founder and General Manager Operations & Research of start-up neuroscience and biotechnology companies M.Sc. (Biotechnology), Ph.D (Biochemistry), Executive Management Education (EGMP) from the Indian Institute of Management (IIM- Bangalore)